Lunit vs Qure AI
The global chest X-ray leaders are separated not by clearance, both grade A on regulatory status, but by what each has chosen to prove. Qure AI holds the broadest chest X-ray regulatory footprint in the market, nine products across X-ray and CT plus the qER neurocritical line, and it is the only chest X-ray computer aided detection device the FDA has cleared with a Predetermined Change Control Plan, meaning models can be updated without a new submission. Lunit's distinction is comparative evidence: more than 100 peer reviewed publications in venues from The Lancet Digital Health to JAMA Oncology, including third party head to head validations against competing commercial products, the kind of direct comparison most vendors avoid. If your failure mode is regulatory coverage across findings and geographies with models that stay current, start with Qure. If your failure mode is proving to a committee how the tool performs against alternatives, start with Lunit. In a category where a 2026 study found sensitivity ranging from 21 to 78 percent across chest X-ray AI vendors, that difference in proof posture is the buying question.
- Third party comparison is your bar: the evidence base includes head to head validations against competing commercial products published in peer reviewed venues, a willingness to be benchmarked this index grades explicitly.
- Publication depth: more than 100 peer reviewed publications spanning The Lancet Digital Health, JAMA Oncology, and Radiology across chest X-ray, mammography, and digital breast tomosynthesis.
- Distribution through hardware: deployment at a reported 3,000 plus institutions in more than 40 countries, partly through imaging OEM relationships, which can ride an existing procurement channel.
- Regulatory breadth decides it: nine products across X-ray and CT including the qER neurocritical line, the broadest chest X-ray regulatory footprint in the market.
- Model currency without resubmission: the only chest X-ray computer aided detection device the FDA has cleared with a Predetermined Change Control Plan, so model updates ship without a new submission.
- Findings coverage on plain film: qXR detects, localizes, and categorizes lung nodules, pneumothorax, and pleural effusion, with setting and specialty coverage graded A on this index.
Side-by-Side
| Axis | L Lunit |
Q Qure AI |
|---|---|---|
| AI Centrality | ||
| Autonomy and Oversight Model | ||
| Model and Technology Transparency | ||
| Clinical and Operational Evidence | ||
| AI Safety and PHI Stewardship | ||
| HIPAA and BAA Posture | ||
| Security Certifications and Trust Center | ||
| FDA and Regulatory Status | ||
| AI Governance and Bias Disclosure | ||
| EHR and Interoperability Depth | ||
| Deployment Model and Data Residency | ||
| Commercial Transparency | ||
| Setting and Specialty Coverage |
Institution counts and deployment figures are vendor published. Both vendors grade A on regulatory status and clinical evidence in this index, with those grades resting on regulatory filings and peer reviewed publications rather than vendor assertion alone. The 21 to 78 percent sensitivity range cited in the verdict comes from a 2026 comparative study of chest X-ray AI on lung cancer detection and is cited as a category level finding; this index has not attributed the endpoints of that range to specific vendors. Neither vendor publishes pricing.